EGFR and neoplasm: In this cohort, Giannikopoulus and colleagues demonstrated the presence of SMO gene amplification in tumor biopsies taken at occurrence of resistance to EGFR-TKIs in 12,5% patients [18] concomitantly with MET gene amplification.